> ## Content Index > Fetch the complete content index at: https://www.melaninblissmedia.com/llms.txt > Use this file to discover other available public pages before exploring further. # Diabetes Care Is More Than a Number - URL: https://www.melaninblissmedia.com/diabetes-care-is-more-than-a-number/ - Published: 2026-11-05T19:35:06.000Z - Updated: 2026-11-05T23:10:05.000Z - Description: The first National Diabetes Month article follows the daily work behind a treatment plan. - Author: Amber McClendon - Tags: Health *The first National Diabetes Month feature follows the daily work behind a treatment plan: who explains it, who pays for it, and who is responsible for the next step.* --- A laboratory number can start a conversation, but it cannot describe the whole person receiving it. Diabetes care involves medication, information, monitoring, food, follow-up, and the practical ability to fit those tasks into daily life. It also involves support that should not disappear when someone leaves an appointment. November is National Diabetes Month. The useful question is not whether people have heard of diabetes. It is whether they understand their own plan and can reach the resources required to use it. NIDDK describes management as work shared with a healthcare team, not an isolated test of willpower. This feature follows the plan after the visit ends. It looks at what a result can and cannot tell a person, what a recommendation costs in time and money, and who inside a health system is responsible for each step: who orders the test, who schedules the class, who explains the price, and who tells the patient what the result means. It is not an investigation of any clinic, and it makes no claim about how any one practice performs. | **AN ILLUSTRATIVE SCENARIO (NOT A REAL PERSON)** This is a composite built to organize questions. It is not someone MB interviewed, and it does not describe an actual clinic. An adult with type 2 diabetes leaves a visit with three instructions: start a new medicine, attend a diabetes education class, and return for repeat blood work. At the pharmacy, the medicine costs more than expected. The class is offered at a time that conflicts with the person’s work shift. The lab order sits in the electronic record, and nobody has said who will remind the patient to complete it. Each instruction was medically reasonable. None of them has an owner after the visit. The sections below ask who that owner should be at each step. | | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ## Begin with the condition, not the stereotype Diabetes involves blood glucose that is too high, but different forms have different mechanisms and treatment needs. A person should know which type has been diagnosed, what the findings mean, and what is being recommended. Prevention advice about type 2 diabetes should not be presented as though it applies identically to every form. Reducing the condition to “too much sugar” can hide the actual work: medication, cardiovascular risk, kidney health, eye care, monitoring, and education. It can also turn a clinical discussion into a judgment about a person’s body or behavior. A responsible article explains what a recommendation is for and leaves individual decisions to the person and their qualified team. ## Understand the number without becoming the number A1C reflects average blood glucose over approximately three months. It is useful but does not show every high or low reading or explain what caused a change. Targets and monitoring plans should be individualized. Certain health conditions can also affect interpretation. Two 2026 narrative reviews describe how those conditions can matter. One review states that for most individuals A1C remains reliable, and that clinically significant mismatch between A1C and actual blood glucose occurs in defined groups with confounding conditions such as anemia, hemoglobinopathies and chronic kidney disease. Its authors warn that failing to recognize a mismatch can lead to inappropriate treatment escalation or to therapeutic inertia, and they recommend looking for confounders, considering other markers such as fructosamine, and using continuous glucose monitoring when it is available. They also note that continuous glucose monitors have their own limits, including differences between sensors and device models.A second review proposes a framework for deciding which glucose measure is least likely to mislead when A1C is unreliable. Its authors state that the framework is an interpretive aid and not a validated guideline or diagnostic algorithm. Both papers are narrative reviews. They do not measure how often a mismatch goes unnoticed in American clinics, and neither can tell a reader whether their own result is affected. What they support is a narrow point: when a home reading and a laboratory result do not agree, the disagreement is information, and the clinician should hear about it. Instead of asking whether a result makes someone a good or bad patient, ask what it means for the plan. Is another test needed? Should monitoring change? What would make the person contact the team before the next visit? If home readings and the laboratory result seem inconsistent, bring that information to the clinician. Do not change medicine based on an article or a single reading without appropriate guidance. ## A recommendation has a workload An instruction can be medically reasonable and still be difficult to carry out. What does the supply cost? Is a device understandable? Can the person attend an education session during work hours? Does the plan fit the actual meal and medication schedule? These are questions, not excuses. They help distinguish an unwillingness to participate from an unresolved barrier. MB should investigate rather than assume which explanation applies. A practical appointment can include an invitation to identify the hardest part. “What will make this difficult at home?” is more informative than “You understand, right?” The answer can reveal what needs another explanation or a different arrangement. Food is one of those arrangements. A 2026 quality improvement study from Michigan enrolled 83 adults with type 2 diabetes and low income or food insecurity from 21 primary care practices. For three months, participants received US $80 a month toward grocery delivery, along with low-carbohydrate educational materials. In the 68 participants with usable data, average A1C fell by 0.4 percentage points, and by 0.7 among the 38 who began with uncontrolled A1C. This was a nonrandomized program with no control group, and 89% of the participants whose race was recorded were White. It cannot show that the groceries caused the change. It does show that a program can address a logistical barrier directly. ## The team is more than a list of names NIDDK describes roles for clinicians, diabetes educators, pharmacists, dietitians, and mental-health professionals. Not every person needs the same arrangement, and availability varies. Knowing a service exists is different from having an appointment. If a referral is recommended, ask where it goes, what coverage applies, and who follows up. A directory is not evidence that the service accepts the insurance or has an opening at a workable time. The best-documented example of this gap concerns education. A cluster randomized trial in 66 UK general practices, with clinical data from 92,977 patients with type 2 diabetes, tested an “Embedding Package” meant to get referral to structured self-management education built into routine practice. The trial’s own introduction states that referral and attendance rates for such programs are low. The package did not change A1C between the intervention and control conditions (adjusted mean difference -0.10 mmol/mol, 95% CI -0.38 to 0.18). Twelve months after the intervention, attendance was somewhat higher (adjusted odds ratio 1.13, 95% CI 1.02 to 1.25), with a statistically significant but not clinically significant A1C difference. The ethnographic arm found that the staff hired to support practices struggled to make and keep contact with them, and the authors say barriers to implementation may have weakened the result. Read it carefully. It is a UK primary care trial, and it tested a method of delivering referrals, not the education class itself. A null result for the package does not mean education fails. It means that adding a marketing plan, a referral pathway and a toolkit did not, in this setting, produce a measurable change. The finding points at the connective work between the visit and the class, which may have no named owner. Emotional burden belongs on the team’s list as well. A 2026 guideline from the European Association for the Study of Diabetes defines diabetes distress as the emotional burden that arises from living with, and self-managing, diabetes. Its eight good practice statements include routine discussion of emotional well-being, use of validated tools, collaborative care planning, and availability of psychological support. For adults with type 2 diabetes, it makes conditional recommendations for psychological, psychoeducational and educational interventions to reduce distress. Its authors acknowledge a scarcity of high-quality trials and note that implementation requires training and system-level support. A 2026 meta-analysis of 52 studies of psychotherapy-based interventions in adults with type 2 diabetes reported a reduction in A1C that was greatest at three months (mean difference -0.53 percentage points, 95% CI -0.80 to -0.25), and a reduction in weight at 12 months (mean difference -3.58, 95% CI -5.62 to -1.53).\[10\] The abstract does not describe how much the studies differed in design or quality, and the authors’ explanation for the early A1C change is a hypothesis. A reader should treat the averages as a general signal, not a prediction. ## Who owns the next step? The Back Office of Care is the set of tasks that decide whether a recommendation turns into something a person can do. The table below lists common ones. The right-hand column is a prompt for questions. It does not describe how any practice assigns the work, and in many settings the answer will be different or unclear. Asking is the point. | **Step** | **What to ask** | **Who may own it (varies)** | | ---------- | --------------------------------------------------------------------------- | -------------------------------------- | | Ordering | Which tests are due, and has the order actually been placed? | Clinician, nurse, or care coordinator | | Scheduling | Who books the lab, the class or the specialist, and who reminds me? | Front desk, referral staff, or patient | | Cost | What will the medicine, supplies and class cost me before I leave? | Pharmacy, billing, or benefits staff | | Explaining | Who walks me through how to use a device or a new medicine? | Pharmacist, educator, or nurse | | Result | Who contacts me with the result, and in what time frame? | Ordering clinician or office staff | | Problems | Whom do I call if I cannot afford, tolerate or understand part of the plan? | A named contact at the practice | ## The price of the plan Cost is the clearest example of a workload that the clinical plan does not mention. The review literature gives a sense of its size. A 2025 scoping review reports that one in six patients with diabetes in the United States reports rationing or abandoning medications to save costs. The review identified 29 studies from 2003 to 2023\. Of 16 interventions that reduced diabetes-related co-payments, seven found improved adherence, six found no improvement, and three did not evaluate change over time. Of eight interventions that eliminated all or some costs, five found improvement and two found none. Programs that paired cost reduction with wellness and disease management programs tended to improve short- and long-term adherence, and six evaluations of state or federal policies, such as insulin co-payment caps, had varying effects. A scoping review maps what exists. It does not weigh studies by quality or produce a pooled effect, so these counts describe a mixed literature and not a verdict on any single policy. The authors note that more work is needed on long-term health and utilization outcomes. The 2023 Medicare insulin cap gives a more specific case. The Inflation Reduction Act capped out-of-pocket insulin spending at US$35 a month for Medicare Part D beneficiaries. A 2026 analysis of Medical Expenditure Panel Survey data found that average annual out-of-pocket insulin spending fell from US$359.95 in 2022 to US$214.11 in 2023, with reductions consistent across demographic subgroups. Even so, 13.2% of Part D beneficiaries spent more than US$420 in 2023, the amount a US$35 monthly cap would imply over a year, and rates of cost-related medication nonadherence did not change. This is a survey-based comparison of two years in one insurance program. It cannot show why some people exceeded the annualized amount, and it says nothing about people with other insurance or none. It supports two statements that can both be true: a price cap lowered average spending, and a cap does not by itself guarantee that everyone can afford the plan. The practical advice is direct. Do not silently ration or stop a prescribed treatment. Tell the prescriber or pharmacist what is preventing use so options can be discussed. ## Technology and who gets it Continuous glucose monitors are one of the tools clinicians now discuss most often. A 2026 review of studies from 2020 to 2025 reports that use of continuous glucose monitoring in adults with type 2 diabetes is associated with improvements in A1C, time in range and self-management, and that cost-effectiveness analyses are favorable. The same review reports that uptake remains uneven, with persistent disparities by age, race and ethnicity, insurance coverage and care setting. A 2024 systematic review of 36 studies on disparities in monitor and insulin pump use in the United States found disparities across race, ethnicity and insurance type. Most of its studies concerned type 1 diabetes, and only two included people with type 2 diabetes. Neither review can say how a given clinic decides who is offered a device. The second one is explicit about its own gap: evidence about type 2 diabetes, about continued use over time, and about several populations is thin. For MB, the reporting question is simple. When a device is recommended, who checks coverage, who teaches its use, and who follows up when it is not working? ## Protecting more than blood glucose Diabetes management includes attention to blood pressure, cholesterol, kidney health, eyes, and feet, as appropriate. NIDDK’s ABC framework includes A1C, blood pressure, and cholesterol. Its discussion of diabetes standards also describes medication choices that address cardiovascular or kidney risk for selected patients.That is not a recommendation that everyone needs the same medicine. It is a reason to ask why a particular treatment is being offered, what benefits are expected, what side effects matter, and what alternatives exist if cost prevents access. ## Support without surveillance Family support can mean a ride, help preparing questions, or time to attend an appointment. It does not have to mean monitoring every plate or commenting on every choice. Ask what help is wanted and preserve the person’s place in decisions. The diabetes distress guideline cited above lists collaborative care planning among its good practice statements.A plan that a person helped to write is more likely to fit the way they live, and a relative who is invited into that conversation can offer help that was requested instead of help that feels like inspection. | **WHAT THE EVIDENCE CAN AND CANNOT TELL US** It can tell us that A1C is reliable for most people and can mislead in defined situations, that education and psychological support have been linked to better A1C in some studies, and that out-of-pocket cost and unequal access to technology are documented barriers. It cannot tell us how any particular clinic, pharmacy or health system handles referrals, prices or follow-up. The studies cited come from the United Kingdom, Michigan, a national Medicare survey, and international reviews. It cannot tell us which instruction an individual should follow. Several of the papers are narrative or scoping reviews, one is a nonrandomized quality improvement report, and the guideline authors themselves describe the trials behind it as scarce. It cannot tell us that a person who struggles with a plan is unwilling. In the sources reviewed, cost, access and system design are named barriers. | | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | **QUESTIONS TO ASK AT THE NEXT VISIT** Which type of diabetes do I have, and what is this recommendation meant to do? What does this result mean for my plan? Is another test needed, and when? Should my monitoring change? What would make me call before the next visit? What will the medicine, supplies and class cost me, and what are the alternatives if I cannot afford them? Who is responsible for the referral, and how will I know it was received and scheduled? Does the class or appointment time work with my job and transportation? If not, is there another option? Is anyone on the team available to talk about the emotional side of managing diabetes? Whom do I call if I am not able to follow part of the plan? For MB, success is not demonstrated by a brochure being handed over. It requires understandable information and a workable next step. This November, know your numbers, and also know what they mean, what the plan requires, and what support you can reasonably ask for. General information, not individual medical advice. For emergencies, seek immediate help. The conversation continues. ■ ■ ■ **SOURCES (PEER-REVIEWED WORK RETRIEVED FROM PUBMED; DOI LINKS INCLUDED)** \[1\] Speight J, Hermanns N, Jensen W, et al. 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetes. Diabetologia. 2026;69(12):3344-3369\. DOI: https://doi.org/10.1007/s00125-026-06840-0 (PMID 42744915) \[2\] Borden CG, Wang R, Everhart AO, Karaca-Mandic P, Dusetzina SB, McCoy RG, Lipska KJ. Out-of-pocket insulin spending before and after the Inflation Reduction Act across demographic subgroups. Health Aff Sch. 2026;4(7):qxag165\. DOI: https://doi.org/10.1093/haschl/qxag165 (PMID 42428250) \[3\] Shenoy DA, Cummins L, Kaplan S, Zullig LL, Sloan CE. Interventions addressing cost-related medication nonadherence in diabetes: a scoping review. Am J Manag Care. 2025;31(Spec No. 15):SP1108-SP1117\. DOI: https://doi.org/10.37765/ajmc.2025.89861 (PMID 41512272) \[4\] Davies MJ, Bodicoat DH, Brennan A, Dixon S, Eborall H, Glab A, et al. Uptake of self-management education programmes for people with type 2 diabetes in primary care through the embedding package: a cluster randomised control trial and ethnographic study. BMC Prim Care. 2024;25(1):136\. DOI: https://doi.org/10.1186/s12875-024-02372-x (PMID 38664727) \[5\] Perini Villanueva G, Solorzano WM, Everett E. Continuous glucose monitoring in type 2 diabetes: clinical outcomes, disparities in access, and cost-effectiveness. Curr Diab Rep. 2026;26(1). DOI: https://doi.org/10.1007/s11892-026-01631-8 (PMID 42329523) \[6\] Patel PM, Thomas D, Liu Z, Aldrich-Renner S, Clemons M, Patel BV. Systematic review of disparities in continuous glucose monitoring and insulin pump utilization in the United States: key themes and evidentiary gaps. Diabetes Obes Metab. 2024;26(10):4293-4301\. DOI: https://doi.org/10.1111/dom.15774 (PMID 39010293) \[7\] Sureshkumar P, Kumar SS, Anusree E, Cheriyan J, Masood A. Navigating the discordance: a comprehensive review of HbA1c-glycemia mismatch in clinical practice. Diabetes Res Clin Pract. 2026;235:113216\. DOI: https://doi.org/10.1016/j.diabres.2026.113216 (PMID 41856328) \[8\] Wu T, Guan Z, Cai W. Glycemic assessment when hemoglobin A1c is unreliable: a clinical-laboratory framework for kidney disease, anemia, and hemoglobinopathies. Front Endocrinol (Lausanne). 2026;17:1898713\. DOI: https://doi.org/10.3389/fendo.2026.1898713 (PMID 42745822) \[9\] Waselewski M, Waselewski E, Oshman L, Hatch K, Chang T. Hemoglobin A1c and weight changes associated with grocery delivery and low-carbohydrate education in adults with type 2 diabetes and food insecurity: observational quality improvement cohort study. JMIR Form Res. 2026;10:e89459\. DOI: https://doi.org/10.2196/89459 (PMID 42766389) \[10\] Rohilla R, Walia R. Effects of psychotherapy interventions on glycemic control and weight loss in adults with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026:113575\. DOI: https://doi.org/10.1016/j.diabres.2026.113575 (PMID 42762920) \[11\] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Team-based diabetes care and diabetes overview pages \[12\] NIDDK. Diabetes management, A1C and insulin resistance, and diabetes standards pages.